Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by: (1) legal requirements and (2) the ethical standard that all human subjects research should be publicly accessible to contribute to generalisable knowledge. Design: Cross-sectional analysis of all clinical trials submitted to the Food and Drug Administration (FDA) for drugs approved in 2012, sponsored by large biopharmaceutical companies. Data sources: Information from Drugs@FDA, ClinicalTrials.gov, MEDLINE-indexed journals and drug company communications. Main outcome measures: Clinical trial registration and results reporting in ClinicalTrials.gov, publication in the medical literature, and compliance with the 2007 FDA Amendments Acts (FDAAA), analysed on the drug level. Results: The FDA approved 15 drugs sponsored by 10 large companies in 2012. We identified 318 relevant trials involving 99 599 research participants. Per drug, a median of 57% (IQR 32–83%) of trials were registered, 20% (IQR 12–28%) reported results in ClinicalTrials.gov, 56% (IQR 41–83%) were published, and 65% (IQR 41–83%) were either published or reported results. Almost half of all reviewed drugs had at least one undisclosed phase II or III trial. Per drug, a median of 17% (IQR 8–20%) of trials supporting FDA approvals were subject to FDAAA mandated public disclosure; of these, a median of 67% (IQR 0–100%) were FDAAA-compliant. 68% of research participants (67 629 of 99 599) participated in FDAAA-subject trials, with 51% (33 405 of 67 629) enrolled in non-compliant trials. Transparency varied widely among companies. Conclusions: Trial disclosures for new drugs remain below legal and ethics standards, with wide variation in practices among drugs and their sponsors. Best practices are emerging. 2 of our 10 reviewed companies disclosed all trials and complied with legal disclosure requirements for their 2012 approved drugs. Ranking new drugs on transparency criteria may improve compliance with legal and ethics standards and the quality of medical knowledge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E., & Krumholz, H. M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000144 · Cited by 401 · cited 1×
“▪ This study takes a uniquely comprehensive approach, analysing five critical elements of transparency for trials of new drugs: (1) registration, (2) results reporting, (3) publication in a medical journal, (4) compliance with legal disclosure requirements and (5) adherence with the ethics standards enshrined in the C…”
BackgroundSelf-citationCompliance with Results Reporting at ClinicalTrials.gov
Anderson, M. L., Chiswell, K., Peterson, E. D., Tasneem, A., Topping, J., & Califf, R. M. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1409364 · Cited by 380
Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis
Ross, J. S., Tse, T., Zarin, D. A., Xu, H., Zhou, L., & Krumholz, H. M. (2012) · BMJ · doi:10.1136/bmj.d7292 · Cited by 371
Self-citationNon-publication of large randomized clinical trials: cross sectional analysis
Jones, C. W., Handler, L., Crowell, K. E., Keil, L. G., Weaver, M. A., & Platts-Mills, T. F. (2013) · BMJ · doi:10.1136/bmj.f6104 · Cited by 350 · cited 2×
“▪ This study takes a uniquely comprehensive approach, analysing five critical elements of transparency for trials of new drugs: (1) registration, (2) results reporting, (3) publication in a medical journal, (4) compliance with legal disclosure requirements and (5) adherence with the ethics standards enshrined in the C…”
BackgroundPublication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
Lee, K., Bacchetti, P., & Sim, I. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050191 · Cited by 215 · cited 1×
“▪ This study takes a uniquely comprehensive approach, analysing five critical elements of transparency for trials of new drugs: (1) registration, (2) results reporting, (3) publication in a medical journal, (4) compliance with legal disclosure requirements and (5) adherence with the ethics standards enshrined in the C…”
Background
Cited by
Full publication of results initially presented in abstracts
Scherer, R. W., Meerpohl, J. J., Pfeifer, N., Schmucker, C., Schwarzer, G., & von Elm, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000005.pub4 · Cited by 307
Anti-corruption, transparency and accountability in health: concepts, frameworks, and approaches
Vian, T. (2020) · Global Health Action · doi:10.1080/16549716.2019.1694744 · Cited by 249
Schmucker, C. M., Blümle, A., Schell, L. K., Schwarzer, G., Oeller, P., Cabrera, L., von Elm, E., Briel, M., Meerpohl, J. J., & on behalf of the OPEN consortium (2017) · PLOS ONE · doi:10.1371/journal.pone.0176210 · Cited by 227
Strengthening Research through Data Sharing
Warren, E. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607282 · Cited by 116
Bashir, R., Bourgeois, F. T., & Dunn, A. G. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0518-3 · Cited by 47
Metadata
- Authors
- Miller, J. E., Korn, D., & Ross, J. S.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2015-11
- Volume
- 5
- Issue
- 11
- Pages
- e009758
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2269763616
- Cited by
- 92
- References
- 7
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. https://app.cochat.ai/papers/10.1136/bmjopen-2015-009758
- The paper
- Miller, J. E., Korn, D., & Ross, J. S. (2015). Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open. https://doi.org/10.1136/bmjopen-2015-009758
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.